Risperdal licence extension

Risperdal tablets, solution and Quicklet tablets have two additional licensed indications.

They are now indicated in the short-term treatment of persistent aggression associated with moderate to severe Alzheimer's dementia unresponsive to non-pharmacological approaches and where there is a risk of harm to self or others.

They are also indicated in the short-term treatment of children with conduct disorder from the age of five years and adolescents with sub average intellectual functioning or mental retardation, diagnosed to DSM-IV criteria.

Treatment in children and adolescents should be by a specialist in child neurology and child and adolescent psychiatry.

View Risperdal drug record

Further information: Janssen-Cilag

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Omega-3 supplements withdrawn from secondary prevention use

Omega-3 supplements withdrawn from secondary prevention use

Omega-3 fatty acids can no longer be prescribed to...

MIMS supplement on contraception and HRT

MIMS supplement on contraception and HRT

The December issue of MIMS includes a special supplement...

Drug shortages - live tracker

Drug shortages - live tracker

Added: clonidine.
Use our constantly updated shortages...

Prescribers reassured over metformin contamination

Prescribers reassured over metformin contamination

Trace amounts of the potential carcinogen N-nitrosodimethylamine...